Kunio Matsumoto Selected Research

Erlotinib Hydrochloride (CP 358,774)

6/2014	Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
7/2013	The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
1/2013	mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
10/2012	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
7/2012	Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
4/2011	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
1/2010	Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
11/2009	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
11/2008	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kunio Matsumoto Research Topics

Disease

74	Neoplasms (Cancer) 01/2023 - 02/2002
24	Lung Neoplasms (Lung Cancer) 01/2020 - 02/2002
19	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2002
14	Fibrosis (Cirrhosis) 01/2013 - 01/2002
12	Pancreatic Neoplasms (Pancreatic Cancer) 04/2011 - 01/2002
9	Wounds and Injuries (Trauma) 05/2015 - 11/2002
9	Ischemia 01/2014 - 06/2001
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 07/2004
4	Adenocarcinoma of Lung 10/2023 - 08/2002
4	Stomach Neoplasms (Stomach Cancer) 01/2022 - 09/2004
4	Mesothelioma 10/2020 - 10/2010
4	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2013 - 07/2002
4	Brain Ischemia (Cerebral Ischemia) 10/2006 - 07/2004
3	Colonic Neoplasms (Colon Cancer) 01/2023 - 06/2004
3	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2006
3	Ascites 01/2022 - 09/2004
3	Malignant Mesothelioma 10/2020 - 10/2010
3	Acute Kidney Injury (Acute Renal Failure) 01/2014 - 03/2009
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2013 - 04/2005
3	Respiratory Hypersensitivity 08/2012 - 04/2005
3	Reperfusion Injury 01/2012 - 02/2002
3	Embolism (Embolus) 10/2006 - 07/2004
3	Peripheral Arterial Disease 02/2004 - 09/2002
2	Fatty Liver 01/2023 - 02/2002
2	Peritoneal Neoplasms 01/2022 - 12/2013
2	Hypoxia (Hypoxemia) 10/2017 - 02/2013
2	Disease Progression 03/2017 - 03/2006
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 05/2015 - 10/2014
2	Spinal Cord Injuries (Spinal Cord Injury) 05/2015 - 10/2014
2	Chronic Renal Insufficiency 01/2014 - 03/2011
2	Renal Insufficiency (Renal Failure) 01/2013 - 01/2002
2	Asthma (Bronchial Asthma) 08/2012 - 01/2008
2	Cardiomyopathies (Cardiomyopathy) 06/2012 - 07/2002
2	Myocardial Ischemia (Ischemic Heart Diseases) 06/2012 - 01/2012
2	Hypertrophy 03/2011 - 05/2005
2	Lung Injury 03/2009 - 09/2007
2	Alcoholic Fatty Liver 08/2008 - 02/2002
2	Chronic Kidney Failure (Chronic Renal Failure) 05/2008 - 01/2002
2	Inflammation (Inflammations) 01/2008 - 04/2005
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2006 - 12/2005
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2005 - 07/2004
2	Infections 01/2005 - 07/2004

Drug/Important Bio-Agent (IBA)

85	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2023 - 01/2002
18	Tyrosine Kinase InhibitorsIBA 04/2022 - 11/2008
18	ErbB Receptors (EGF Receptor)IBA 10/2019 - 11/2008
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
14	Proto-Oncogene Proteins c-metIBA 01/2022 - 08/2002
12	Gefitinib (Iressa)FDA Link 11/2013 - 03/2006
11	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2023 - 05/2002
9	Phosphotransferases (Kinase)IBA 01/2023 - 05/2003
9	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2014 - 11/2008
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 09/2011
8	LigandsIBA 10/2019 - 08/2006
7	CollagenIBA 10/2020 - 07/2002
7	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2013 - 04/2003
7	Angiogenesis InhibitorsIBA 12/2009 - 02/2002
6	DNA (Deoxyribonucleic Acid)IBA 06/2017 - 02/2004
6	tyrosine receptor (receptor, tyrosine)IBA 03/2016 - 05/2003
6	CytokinesIBA 07/2013 - 08/2002
5	CrizotinibIBA 03/2016 - 07/2012
5	ThromboxanesIBA 01/2013 - 01/2012
5	ONO 1301IBA 01/2013 - 01/2012
5	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2011 - 04/2003
4	Peptides (Polypeptides)IBA 01/2023 - 02/2002
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2017
4	Neutralizing AntibodiesIBA 10/2017 - 09/2012
4	AntibodiesIBA 08/2012 - 01/2005
4	Therapeutic UsesIBA 08/2012 - 01/2002
4	Matrix Metalloproteinases (MMPs)IBA 08/2011 - 06/2004
4	Transforming Growth Factor beta1 (TGF beta 1)IBA 03/2006 - 11/2002
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 09/2012
3	WZ4002IBA 01/2013 - 03/2012
3	Messenger RNA (mRNA)IBA 01/2013 - 08/2002
3	Immunoglobulin G (IgG)IBA 06/2012 - 05/2008
2	matrigelIBA 10/2023 - 02/2002
2	Indicators and Reagents (Reagents)IBA 01/2023 - 01/2017
2	Bevacizumab (Avastin)FDA Link 10/2017 - 06/2014
2	Anaplastic Lymphoma KinaseIBA 03/2017 - 03/2016
2	alectinibIBA 03/2016 - 07/2014
2	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2014 - 03/2006
2	4- (2- fluoro- 4- ((((2- phenylacetyl)amino)thioxomethyl)amino)phenoxy)- 7- methoxy- N- methyl- 6- quinolinecarboxamideIBA 06/2014 - 12/2013
2	Glycerol (Glycerine)FDA LinkGeneric 01/2014 - 01/2013
2	Tyrosine (L-Tyrosine)FDA Link 07/2013 - 10/2010
2	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2013 - 03/2012
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 07/2013 - 01/2013
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2013 - 11/2008
2	Mitogen-Activated Protein KinasesIBA 02/2013 - 05/2004
2	AfatinibIBA 01/2013 - 03/2012
2	Collagen Type I (Type I Collagen)IBA 01/2013 - 05/2005
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 09/2011 - 06/2004
2	Culture MediaIBA 04/2009 - 03/2008
2	Cisplatin (Platino)FDA LinkGeneric 04/2009 - 09/2004
2	Complementary DNA (cDNA)IBA 04/2007 - 10/2002
2	Bleomycin (Blenoxane)FDA LinkGeneric 07/2005 - 07/2004
2	Transforming Growth Factor beta (TGF-beta)IBA 04/2005 - 01/2002

Therapy/Procedure

21	Therapeutics 04/2022 - 01/2002
5	Intraperitoneal Injections 12/2013 - 02/2002
4	Microspheres (Microsphere) 10/2006 - 07/2004
3	Aftercare (After-Treatment) 03/2017 - 10/2005
3	Radiotherapy 01/2010 - 05/2003